- Revenue Cycle Management
- COVID-19
- Reimbursement
- Diabetes Awareness Month
- Risk Management
- Patient Retention
- Staffing
- Medical Economics® 100th Anniversary
- Coding and documentation
- Business of Endocrinology
- Telehealth
- Physicians Financial News
- Cybersecurity
- Cardiovascular Clinical Consult
- Locum Tenens, brought to you by LocumLife®
- Weight Management
- Business of Women's Health
- Practice Efficiency
- Finance and Wealth
- EHRs
- Remote Patient Monitoring
- Sponsored Webinars
- Medical Technology
- Billing and collections
- Acute Pain Management
- Exclusive Content
- Value-based Care
- Business of Pediatrics
- Concierge Medicine 2.0 by Castle Connolly Private Health Partners
- Practice Growth
- Concierge Medicine
- Business of Cardiology
- Implementing the Topcon Ocular Telehealth Platform
- Malpractice
- Influenza
- Sexual Health
- Chronic Conditions
- Technology
- Legal and Policy
- Money
- Opinion
- Vaccines
- Practice Management
- Patient Relations
- Careers
Oral, IV steroids offer similar efficacy for COPD
Patients with chronic obstructive pulmonary disease exacerbations treated with low-dose oral corticosteroids have outcomes similar to those treated with more costly and invasive high-dose intravenous corticosteroid therapy, according to new research.
JAMA. 2010;303:2359-2367. [June 16, 2010]
Patients with chronic obstructive pulmonary disease (COPD) exacerbations treated with low-dose oral corticosteroids have outcomes similar to those treated with more costly and invasive high-dose intravenous corticosteroid therapy, according to researchers from Baystate Medical Center in Springfield, Massachusetts. They assembled data on 79,985 patients hospitalized for acute COPD exacerbations at 414 hospitals during 2006 and 2007. In the intravenous group, 1.4 percent died and 10.9 percent experienced treatment failure, while in the oral group, 1.0 percent died and 10.3 percent experienced treatment failure. Furthermore, patients in the oral group had shorter hospital stays and lower costs.
